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Abstract
Background: Estimates of multimorbidity, defined as the presence of at least two chronic conditions, some of which
attributable to modifiable behaviours, are high in adults with cerebral palsy (CP). An assessment protocol evaluating
multimorbidity risk is needed in order to develop and evaluate effective interventions to optimize lifelong health in
individuals with CP. The aim of this protocol paper is to describe the development of a core outcome set (COS) for
assessing multimorbidity risk in adolescents and adults with CP, to be used in clinic and research.
Methods: The expert consortium will first define the target population and outcomes to be measured. Through a
process of literature review and an international Delphi survey with expert clinicians and researchers, we will then
determine which outcome measurement instruments (OMIs) can best measure those outcomes. The resulting OMIs
will be used in a feasibility study with adolescents and adults with CP from an international clinical research network.
Finally, a face-to-face stakeholder meeting with adolescents and adults with CP, their families/caregivers and
researchers and clinicians who are experts in CP, will be organized to reach final agreement on the COS.
Discussion: This COS will guide clinicians and researchers in assessing multimorbidity risk in adolescents and adults with
CP. The inclusion of experts and individuals with CP from international locations for establishing the COS lends strong
support to its generalizability. Evidence of its feasibility and approval from all stakeholders will enable implementation in
clinical practice, and guide future research using the COS in individuals with CP.
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Background
Cerebral palsy (CP) is a well-recognized neurodevelop-
mental disability commencing in early childhood and con-
tinuing throughout life, and is the most common motor
disability in childhood [1]. The disability itself results from
non-progressive disturbances to the developing fetal or in-
fant brain, and the resultant motor disorders are often
accompanied by disturbances of cognition, behaviour and
communication, to name only a few [2]. Population-based
studies report prevalence estimates of CP ranging from
1.5 to greater than 3 per 1000 live births [3–7]. As CP pre-
sents itself early in life, much research has focused on
children with CP; however, given the longer lifespan
apparent in most persons with CP [8], clinicians and
researchers have started to focus on the impact of CP and
associated health issues using a lifespan approach. Indeed,
adults with CP are a growing community who are now
recognised as outnumbering children 3:1 in some coun-
tries [9].
A prominent concern for individuals with CP is their
physical behaviour and reduced cardiorespiratory endur-
ance [10–12]. Physical behaviour is defined as the
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behaviour of a person in terms of body posture (e.g. sit-
ting and standing), movements (e.g. walking and cycling)
and/or daily activities (e.g. sports and gardening) in his/
her own environment, and therefore consists of both
physical activity and sedentary behaviour [13]. Cardiore-
spiratory endurance is the capacity of the body to perform
physical activity, which is dependent mainly on the aerobic
or oxygen-requiring energy systems [10]. Adolescents and
adults with CP have reduced cardiorespiratory endurance
[14], which is a risk factor for cardiovascular disease and
cardiovascular-related mortality [11]. Also, children,
adolescents and adults with CP engage in significantly less
physical activity and more sedentary behaviour compared
to typically developing peers [15–19]. Low levels of phys-
ical activity and more sedentary behaviour can partly be
explained by reduced mobility following from the condi-
tion itself, and by accompanying physical pain and fatigue
that progressively worsen with aging [20]. There are differ-
ences among individuals with CP in their physical activity
levels [21] and in the prevalence of obesity [22], which are
contingent upon the functional status of individuals, as
determined by the Gross Motor Function Classification
System (GMFCS) [23]. Lower cardiorespiratory endurance
and physical activity and more sedentary behaviour are as-
sociated with risk of cardiovascular disease (i.e. coronary
heart disease, cerebrovascular disease, peripheral arterial
disease) and cardiometabolic disease (i.e. diabetes mellitus
and obesity) in persons with CP [17, 24, 25], which may
become higher later in life [26, 27]. Recent research in
middle-aged adults with CP revealed high estimates of
multimorbidity, which were significantly more prevalent
among obese versus non-obese persons with CP [12].
Multimorbidity has been defined as the presence of at least
two chronic conditions [12]. Among individuals with CP, re-
ports are emerging of chronic conditions apart from CP
itself, such as hypertension, dyslipidaemia, hyperglycaemia,
insulin resistance and obesity [17, 24, 26]. Results from a
population-representative sample of adults with CP showed
that this population has significantly greater age-adjusted
prevalence of hypertension (30.0% vs. 22.1%) and obesity
(41.4% vs. 29.7%) compared to adults without CP [28].
Despite the significant progression of disability that is
known to occur during the aging process in CP [20],
there has been a lack of attention devoted to under-
standing the pathophysiology of the development of
multimorbid conditions in adolescents and adults with
CP, beyond those stemming from the primary brain in-
jury in infancy. Risk of multimorbidity could be attrib-
uted to a shared number of modifiable behaviours such
as physical inactivity and/or sedentary lifestyles, poor
diet and inadequate sleep [29]. This highlights the
importance of screening for, and understanding of expos-
ure to factors that increase the risk of multimorbidity in
individuals with CP.
Over the last decade, a number of generic and
CP-specific instruments and protocols assessing multi-
morbidity risk factors have been developed. As a result,
studies evaluating these risk factors in adolescents and
adults with CP are using a variety of outcome measure-
ment instruments (OMIs) (e.g. self-report questionnaires,
accelerometry-based activity monitors, biomarkers and
performance-based tests), which might be measuring the
same outcome, and thus causing difficulty synthesizing
knowledge from the published literature and when gener-
alizing findings [30]. Moreover, the psychometric quality
(i.e. reliability, validity, sensitivity) of OMIs tends to vary
and/or published evidence is lacking, altogether making it
inconvenient for clinicians and researchers to select the
most appropriate OMIs for the outcome of interest. In
order for clinicians and researchers to work with individ-
uals with CP on plans for effective interventions - includ-
ing advice pertaining to physical behaviour, nutrition and
sleep - to reduce multimorbidity risk, it is vital to reach
consensus on which outcomes to assess, the ways to assess
them, and ultimately leading to their inclusion in routine
clinical practice.
Lately, there is increasing recognition of the need to
identify core sets of outcomes that enable comparison of
clinical trials in a particular condition. Moreover, estab-
lishing a core outcome set (COS) may be useful for rou-
tine health screening. Currently, there is no established
COS for adolescents and adults with CP for the purpose
of evaluating multimorbidity risk factors. A search of
“cerebral palsy” through the Core Outcome Measures in
Effectiveness Trials (COMET) database resulted in six
matches, all of which focus on children with CP [31].
There are common data elements (CDEs) for CP due to
a joint effort between the CP CDE Working Groups and
the National Institute of Neurological Disorders and
Stroke [32]. Within the CDEs is a summary of core and
supplemental recommendations that is highly recom-
mended as a start-up resource for clinical research in
this population. Although this set of CDEs was recently
developed (2016), it only applies to children and adoles-
cents aged 0–18 years and does not specify instruments
specific to adults with CP or measures that assess multi-
morbidity risk [33].
The aim of this protocol paper is to describe the
process of developing a COS of OMIs for multimorbid-
ity risk in adolescents and adults with CP, to be used in
clinic and research. This work includes (1) identifying
what outcomes should be measured; (2) determining
how to best measure those outcomes and (3) measuring
these outcomes in an international cohort of individuals
with CP. The final COS will be made in consultation
with individuals with CP and their families and care-
givers and with representatives of the clinical and
research community who are working with people with
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CP. The inclusion of adolescents and adults with CP and
their families and caregivers is critical to ensure that
OMIs are meaningful, appropriate, and acceptable to in-
form decisions about the assessment of multimorbidity
risk in this population. We will include adolescents with
CP in the assessments of multimorbidity risk, as this will
capture a pivotal transition period, and may highlight
the importance of engaging in positive behaviours early
on to attenuate multimorbidity risk later in life. This
study is part of a programme of research aiming to
ultimately understand, treat and prevent multimorbidity
in adolescents and adults with CP through modifiable
behaviours (e.g. physical behaviour, sleep and nutrition),
and to develop an international database that will allow
for harmonization of data and the ability to document
changes over time in this population.
Methods
This study protocol is registered with the COMET Ini-
tiative (http://www.comet-initiative.org/studies/details/
1130) and follows recently published guidelines from a
collaboration between the COMET Initiative and
Consensus-based standards for the selection of health
measurement instruments (COSMIN) [30]. Slight adjust-
ments were made to the original flowchart [30], as we
chose to include a pilot testing phase (Fig. 1). Phase 1
has begun, and the target population and outcomes to
be measured have already been defined.
Investigators and co-investigators
Four authors (PM, JB, MR and JWG) will have an inves-
tigating role in the COS development. After deciding on
the conceptual considerations in consultation with
co-investigators (MP, EH, WS, AB, OV and RB), they will
first review the literature and extract relevant OMIs.
Second, they will carry out a consensus procedure with
experts to obtain agreement on selected OMIs to be
included in the COS. Third, they will coordinate a
cross-sectional feasibility study in which the COS will be
tested in an international cohort of adolescents and
adults with CP at four sites. Finally, they will organize a
stakeholder meeting to review and finalize the COS of
OMIs for multimorbidity risk.
Phase 1: selecting relevant OMIs
Step 1: conceptual considerations We defined a target
population and outcomes to be measured, in line with
the COSMIN-COMET guideline [30]. This was done via
an in-person meeting with the co-investigators from four
research centres (Hamilton, Canada; Ann Arbor, USA;
Rotterdam and Utrecht, The Netherlands), at the 29th
European Academy for Childhood Disability conference
(2017). During this meeting, the target population was
defined as adolescents (14–18 years of age) and/or adults
(> 18 years of age) with CP. Furthermore, the following
outcomes were decided to be important for assessing
multimorbidity risk in the target population: physical
behaviour, nutrition, sleep, cardiorespiratory endurance,
body composition, blood pressure and lipids/glucose. In-
cluding risk behaviours (i.e. physical behaviour, nutrition
and sleep) is important to identify which patients require
intervention. Measuring cardiorespiratory endurance,
body composition, blood pressure and lipids/glucose will
allow clinicians and researchers to observe the benefits
of improved risk behaviours.
Step 2: finding existing OMIs In order to find all exist-
ing OMIs addressing the defined outcomes, we will use
three sources of information, including (1) existing system-
atic reviews, (2) literature searches and (3) additional
sources (e.g. conference proceedings) [30]. Additional
sources are considered optional since it is unlikely that one
will find OMIs of good quality that were not already identi-
fied from a systematic search of the literature [30].
The COSMIN database of systematic reviews of OMIs
will be consulted to see if there are any systematic reviews
that describe our target population and any of the seven
outcomes. Candidate OMIs for each outcome will further
be identified by electronic searches of the following data-
bases: EMBASE and Medline (Ovid), PsycINFO and
Pubmed. The electronic searches will be carried out by two
researchers with experience in conducting systematic re-
views (PM and JB). We will develop a search strategy that
will include the following major themes: “cerebral palsy”,
“adolescent OR adult” and each outcome on its own. Key
terms within the search strategy will be aligned to medical
subject headings and expanded to include more descriptive
terms. Searches consistent with “measurement properties”
will not be included in the search strategy, since evidence
on the measurement properties of relevant OMIs is ex-
pected to be limited in our target population, exposing a
risk of missing relevant studies (see Additional file 1).
Eligible publications will be randomized controlled trials,
longitudinal studies (including experimental and cohort
studies) and observational studies (including cross-sec-
tional, cohort, and case-control studies) written in English.
Studies will be grouped by outcome and repeated where
appropriate (i.e. if there is > 1 outcome within a single
study). The two researchers will independently screen titles
and abstracts and select references using a predetermined
set of inclusion/exclusion criteria (see Additional file 2). If
there are any discrepancies, these will be resolved by con-
sulting other investigators (JWG and MR). Upon agree-
ment on the final selection of studies, the two researchers
will record each OMI for each outcome used in an eligible
study. We will also extract characteristics of the study sam-
ple (i.e. sample size, mean age, sex, type of CP and GMFCS
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level(s)). Data extracted will be crosschecked for compari-
son of accuracy between the two researchers.
A group of experts that will be consulted during the sec-
ond phase of the COS development process will serve as
additional sources for finding OMIs. The group will be
requested to provide any additional OMIs that are consid-
ered relevant to an outcome but were not identified in
current systematic reviews or in the literature searches.
Step 3: quality assessment of the OMIs The quality of
the OMIs that result from step 2 will be assessed in
accordance with the COSMIN-COMET guideline [30].
The quality assessment will include two parts: (1)
evaluating the methodological quality of the studies in-
cluded from the literature searches and (2) evaluating
the quality of the OMIs (i.e. their measurement proper-
ties). Since the literature search will not be limited to
studies on the measurement properties of OMIs, we will
use a combination of the COSMIN checklist and the
McMaster critical review form [34, 35]. The COSMIN
checklist will be applied for evaluating the methodo-
logical quality of studies on the measurement properties
of OMIs [34], while the McMaster critical review form
will be applied to assess the methodological quality of
the other study types (e.g. clinical trials and observa-
tional studies) [35]. The quality of the OMIs will be
Fig. 1 Main steps in the core outcome set (COS) development including roles of all involved at each step. Schematic outline of the different phases
and steps included in the development of a COS for multimorbidity risk assessment in adolescents and adults with cerebral palsy. Roles of all involved
at each step are indicated. OMI, outcome measurement instrument; CP, cerebral palsy
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evaluated by applying criteria for good measurement
properties [36]. We will first evaluate the content validity
of the included OMIs and where applicable the
remaining measurement properties [30]. Both re-
searchers (PM and JB) will perform the OMI evaluation,
and will crosscheck each other’s quality assessments to en-
sure accuracy and completeness. Evaluations of the meth-
odological quality of the studies and the quality of the
OMIs will be combined into a best evidence synthesis,
grading the body of evidence for each OMI [30]. Feasibil-
ity aspects of the OMIs including applicability (for the tar-
get population), patient feasibility, assessor/clinician
feasibility and practical feasibility will be considered in the
next phase of the study.
Phase 2: consensus procedures: Delphi and online survey
Step 4: select an OMI for each outcome included in
the COS We will use the Delphi survey method [37] as a
consensus procedure to obtain agreement on the selected
OMIs included in developing a COS, performed by experts
in the area of the risk of multimorbidity in adolescents and
adults with CP. In a Delphi procedure, interactions be-
tween experts occur via a series of individual surveys,
preserving both anonymity and balance in the participation
of the experts [38]. In contrast to an in-person consensus
method, a Delphi procedure can be conducted via email
survey and is therefore accessible to participants regardless
of location, and involves no cost [39].
Experts
To remain consistent with the international aspect of
the protocol, we will include a group of eight experts
that consist of clinical and research experts in this field.
The experts will be from Canada (n = 2), USA (n = 2),
and The Netherlands (two locations, n = 4). The investi-
gators (PM, JB, MR and JWG) discussed and confirmed
a priori that each international location must consist of
at least one clinical and one research expert. To be con-
sidered a clinical expert, the individual must have
worked with adolescents and/or adults with CP for at
least 5 years. To be considered a research expert, the in-
dividual must have published one or more articles
related to an identified outcome of multimorbidity risk
in this population (adolescents and/or adults with CP).
Delphi survey
The initial stage of the Delphi survey will be a
pre-round to obtain a list of OMIs that is as
complete as possible. Based on the results from the
literature searches performed by the two researchers,
a list of studies with OMIs will be identified and di-
vided into the seven defined outcomes: (1) physical
behaviour, (2) nutrition, (3) sleep, (4) cardiorespiratory
endurance, (5) body composition, (6) blood pressure
and (7) lipids. Experts will be provided the results
from the literature searches via e-mail, and requested
to provide any additional OMIs that are relevant to
an outcome but are not identified in the literature
searches. These could include OMIs that are being
used in clinical practice, ones used by a colleague,
and/or ones that were read in an abstract or article
or in a student’s thesis. Any proposed OMIs will be
required to have a reference or abstract attached, to
allow the two researchers to evaluate the quality of
both the study and the OMI as per step 3 [30].
In round 1 of the Delphi survey, experts will receive an
updated list of OMIs pertaining to each of the seven out-
comes, which will be delivered by e-mail. The investiga-
tors will provide the experts with a spreadsheet consisting
of seven tabs, one for each outcome. Every tab will include
all associated OMIs that were obtained during step 2 and
the Delphi pre-round, accompanied by a brief note of the
methods/equipment used, a short description of the sam-
ples in which the OMI was used and graded evidence of
the OMI resulting from step 3. A detailed description of
the characteristics of each included study will be provided
separately to assist experts in reviewing the OMIs. Study
characteristics will include author and year of publication,
the outcome(s) studied, the sample characteristics ex-
tracted in step 2 and the methodological quality of the
study evaluated in step 3. Experts will be given detailed in-
structions and an instructional video outlining how to
score each OMI on a 1–10 scale (1 = lowest, 10 = highest)
for five different aspects of feasibility: applicability, patient
feasibility, clinician feasibility, practical feasibility and
overall rating. A comment box will be provided to allow
experts the option to provide additional information to
the researchers (i.e. explain responses or raise concerns),
or to indicate that they are ignorant or uncertain. Experts
will have 2 weeks to score the OMIs for feasibility.
Reminder e-mails will be sent after 1 week and at 1 day be-
fore the end of the 2-week period. Mean scores will be cal-
culated after receiving and aggregating the expert scores.
OMIs with a mean overall score ≥ 7 will be retained, those
with scores < 6 will be omitted and those with scores of
6–7 will be discussed among the investigators using the
expert comments and quality scores. Moreover, we will
examine differences between clinician and researcher
scores and describe these results.
In subsequent rounds of the Delphi survey, experts
will be presented the results from the previous round.
All experts will see aggregated scores for each OMI,
and a synopsis of the comments made by each expert
(if applicable). Experts will be asked to consider the
feedback (i.e. aggregated scores and comment synop-
sis) and again score the feasibility aspects for the
remaining OMIs with an option to provide their
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rationale in a comment box. In these rounds, experts
also will be asked to identify their preferred OMI for
each outcome and to explain why. Similar to round 1,
experts will have 2 weeks to score the OMIs for feasi-
bility with reminder e-mails provided at the same
time points. The expert scores will be processed in a
similar fashion and extended with the preferred OMI
scores. This process will continue until a single OMI
per outcome is selected, based on ≥ 70% agreement
among experts. The investigators will attempt to iden-
tify a provisional COS pertaining to the seven out-
comes from the scores after two rounds. This will be
based on aggregated scores (mean and median), ex-
pert opinion (i.e. rationales and additional information
from the comments) and the quality of the studies
and OMIs. The provisional COS will be presented to
all experts, who will be asked whether they agree or
disagree with the OMI for each outcome in the COS.
If an expert disagrees with the suggested COS, they
will be asked to provide their comments and reasons
for disagreement [40]. From the decisions and
comments made by the experts, a provisional COS
will be presented and evaluated for final agreement.
The COS will only become final after feasibility test-
ing (phase 3) and stakeholder engagement (phase 4)
(see below).
Step 5: patient/family judgement on relevance and
completeness of selected outcomes We will conduct a
short online survey with patients with CP or families/
caregivers of people with CP, to rate the importance
of each outcome as something they would like their
family doctor to measure and discuss with them.
Phase 3: feasibility study
Step 6: feasibility test of the COS in the target
population After developing a COS for multimorbidity
risk assessment for use in clinical research and practice,
the next stage will be to test the feasibility of the COS in
a cohort of adolescents and adults with CP. Aspects of
feasibility to be assessed from the perspectives of the
clinicians and researchers will include ease of assess-
ment, time required for completion and their confidence
in the COS to assess multimorbidity risk. Time require-
ment and interpretation of results will be assessed (see
below) to determine feasibility from the patient
perspective.
Participants
The feasibility study will focus on adolescents and adults
aged 14 years and over, with a diagnosis of CP. We will
include individuals with CP across all GMFCS levels
(levels I–V), from three different international locations:
Hamilton, ON, Canada; Ann Arbor, MI, USA and Rot-
terdam and Utrecht (combined), The Netherlands. The
knowledge to be gained from this multinational study
will be far superior to the minimal information that
would be gained if we were to conduct the study at a
single site, which has constrained the generalizability of
research in this area [41].
Recruitment strategy
Individuals with CP will be recruited during clinical
visits to an adult rehabilitation centre or a child and
youth clinic in Hamilton, ON, Canada; Ann Arbor, MI,
USA and Rotterdam and Utrecht, The Netherlands. Dur-
ing clinical visits, a physician (JWG, EH or WS) or a
study coordinator (PM or JB) from our research team
will introduce the study to the patient, at which point
the patient will have an opportunity to consent to
participate in the study. Members of our team have used
a similar recruitment strategy successfully in the past
[26], and we are confident in achieving a total sample
size of 75 (25 per geographical region) for testing the
feasibility of the COS. As feasibility testing of the COS
will be cross-sectional in nature, we will not include a
control group at this time. We plan for a future grant
application to fund an intervention study using the
findings of our feasibility study, which will incorporate a
control group.
Sample size
An a priori criterion for success of this feasibility study
is that a subsequent intervention trial would be feasible
if the outcome variables were collected for ≥ 70% of par-
ticipants. Using a 95% confidence interval (CI) for the
proportion of eligible participants who complete the
assessment, a margin of error of 0.05, a lower bound CI
of 0.70 and an expected completion rate of 75%, the
required sample for the feasibility study will be at least
75 participants. We aim to recruit five participants per
GMFCS level per location (i.e. 5 participants * 5 GMFCS
levels * 3 locations), for a total of 75 participants. As this
is a cross-sectional study (i.e. single time commitment),
we will not factor in the attrition rate.
Assessments
Eligible participants who have provided written consent
to participate in the feasibility study will be assessed.
Participants will be invited to visit the relevant setting,
in which we will execute the OMIs selected for the COS.
Assessments will be conducted by the clinicians and re-
searchers involved, where applicable with support from
research/laboratory assistants. Based on the outcomes
that have been identified in step 1, we estimate that it
will take 3–4 h to conduct the total set of OMIs. Natur-
ally, the collected data will provide insight into the risk
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profile of the individual participant. We hope that the
measures will be integrated into clinical care as much as
possible. It is conceivable that the total data collection
time may be spread over a single assessment or multiple
assessments (e.g. body composition and blood pressure
measurements in clinic, but an additional session for
measurement of cardiorespiratory endurance). The total
time required will be explored in our feasibility study.
The COS will be qualitatively evaluated to examine its
acceptability as a whole, by both the participants and
clinicians/researchers. After the measurements the
participants will be asked about their experience of the
COS, including time required to complete the assess-
ments, via a short survey. Upon completion of all mea-
surements, we will question the clinicians and
researchers who conducted the assessments about the
ease of assessment, completion time and their confi-
dence in the COS, also via a short survey. Together with
the collected data, the feedback from the participants,
clinicians and researchers will provide a clear indication
of the feasibility of the COS for future use in clinical
research and practice.
Phase 4: patient and family/caregiver engagement
Step 7: final agreement on the COS among stakeholders
As a final step and after taking into consideration the
qualitative evaluations from study participants, clinicians
and researchers, we will organize a face-to-face stake-
holder meeting to reach final agreement on the COS.
Adolescents and adults with CP and their families and/
or caregivers, as stakeholders in this project, will be re-
cruited with support from the American Academy for
Cerebral Palsy and Developmental Medicine (AACPDM)
family/participant education forum. The AACPDM
education forum is held annually at the AACPDM con-
ference. Prior to the meeting, we will work with the
AACPDM administrative leaders to have an advertise-
ment positioned on their website asking for adolescents
and adults with CP (and their families/caregivers) to
participate in a meeting to help review and finalize a
COS for multimorbidity risk. We will invite four adoles-
cents and four adults with CP of varying GMFCS levels,
who did not participate in the feasibility study, and their
families and/or caregivers (if applicable), to take part in
the meeting, which will occur during the AACPDM
2018 conference (9–13 October 2018).
Dissemination
Details of the finalized COS will be disseminated
through publication in a scientific journal, presenta-
tion(s) at international scientific conferences and
research rounds at clinics and academic institutions
at each international location.
Discussion
The aim of this project is to develop and test the feasi-
bility of a COS to assess multimorbidity risk in adoles-
cents and adults with CP. Ultimately, the COS will be
used to understand, treat and prevent multimorbidity in
this population, while being utilized in a clinical and/or
research setting. The development of this COS is
expected to have the potential to be generalized to other
types of child-onset neurodevelopmental disabilities.
A strength of the proposed work is the inclusion of
clinical and research experts in this field (COS develop-
ment) and individuals with CP (feasibility study), from
international locations. The knowledge to be gained
from an international study will be significant and meets
a major limitation in multimorbidity risk research in this
population (i.e. studies of small sample sizes that are
geographically isolated). If we are able to conduct the
feasibility study successfully and receive positive feed-
back from individuals with CP, their families/caregivers
and clinicians and researchers, our next step will be to
apply for funding to conduct an intervention study in
this population aiming to prevent multimorbidity risk,
including other geographic locations worldwide. In the
meantime, the development and feasibility testing of a
COS for adolescents and adults with CP will improve
the consistency of CP research moving forward. Ultim-
ately, we aim to utilize the COS in clinic to work
towards developing a database that will allow for
harmonization of data and the ability to document
changes over time, which will enhance and accelerate
our understanding of multimorbidity risk and presenta-
tion in this population, and will help to overcome the
issues of current small-scale studies. As well, performing
the COS assessment in clinic will allow us to obtain a
risk profile for the patient, which can help inform an in-
dividualized treatment plan.
A challenge we faced with this protocol was selecting
when to engage individuals with CP and their families/
caregivers as key stakeholders in COS development.
Ideally, we would have included these stakeholders
throughout the study from the very beginning to the
end. Despite not including individuals with CP in phase
1 of the project, we believe that the outcomes we se-
lected align with the top research priorities identified in
part by individuals with CP and their families: under-
standing how to prevent secondary impairments related
to aging with CP and identifying effective long-term
exercise strategies to improve activity and health across
their lifespan [42]. Moreover, in addition to the Delphi
survey among professionals, we will also conduct an on-
line patient/family survey to inform us whether the tar-
get population agrees that the outcomes to measure are
relevant. Due to the focus on knowledge synthesis in the
Delphi survey with research rigor and the terminology
McPhee et al. Trials          (2019) 20:176 Page 7 of 9
involved in quality assessments of studies and OMIs, we
decided it would be more pragmatic to develop a
provisional COS amongst clinicians and researchers, and
then bifurcate to feasibility testing and a stakeholder
meeting, to incorporate perspectives from individuals
with CP and their families/caregivers and come to a final
agreement on the COS. A former study that attempted
to develop a COS with patient perspectives from the on-
set of the idea was reported as challenging [43].
Despite an effort to include expert clinicians and re-
searchers working with adolescents and adults with CP
who are knowledgeable of multimorbidity, none of these
individuals considered themselves as experts in the out-
comes of nutrition and sleep in CP. This identifies an
important gap in clinical research in this population; if
nutrition and sleep are to be considered important
components of multimorbidity risk prevention in people
with CP [44], clinicians and researchers need to be
trained in these outcomes in order to assess and manage
these components of health.
Trial status
At the time of submission, we have included experts for
the Delphi survey. Recruitment for the feasibility study
will start in June 2018 subject to the ethics approval
from all institutions involved.
Additional files
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criteria. (DOCX 16 kb)
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